Technical Analysis for CALT - Calliditas Therapeutics AB
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | -0.62% | |
| Bollinger Band Squeeze | Range Contraction | -0.62% | |
| Narrow Range Bar | Range Contraction | -0.62% | |
| Three Weeks Tight | Range Contraction | -0.62% | |
| Oversold Stochastic | Weakness | -0.62% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.54% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.54% |
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| Down 1% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| 10 DMA Resistance | about 9 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/13/2024
Calliditas Therapeutics AB Description
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Pharmacy Medication Pharmaceutical Products Kidney Disease Renal Disease Pharmaceutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 41.9 |
| 52 Week Low | 15.25 |
| Average Volume | 16,047 |
| 200-Day Moving Average | 22.52 |
| 50-Day Moving Average | 29.42 |
| 20-Day Moving Average | 39.22 |
| 10-Day Moving Average | 38.83 |
| Average True Range | 1.01 |
| RSI (14) | 66.67 |
| ADX | 50.01 |
| +DI | 38.74 |
| -DI | 16.35 |
| Chandelier Exit (Long, 3 ATRs) | 38.86 |
| Chandelier Exit (Short, 3 ATRs) | 40.86 |
| Upper Bollinger Bands | 40.70 |
| Lower Bollinger Band | 37.74 |
| Percent B (%b) | 0.34 |
| BandWidth | 7.55 |
| MACD Line | 2.39 |
| MACD Signal Line | 3.11 |
| MACD Histogram | -0.7195 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 39.29 | ||||
| Resistance 3 (R3) | 39.26 | 39.04 | 39.20 | ||
| Resistance 2 (R2) | 39.04 | 38.91 | 39.06 | 39.17 | |
| Resistance 1 (R1) | 38.90 | 38.82 | 38.97 | 38.93 | 39.14 |
| Pivot Point | 38.68 | 38.68 | 38.72 | 38.70 | 38.68 |
| Support 1 (S1) | 38.54 | 38.55 | 38.61 | 38.57 | 38.36 |
| Support 2 (S2) | 38.32 | 38.46 | 38.34 | 38.33 | |
| Support 3 (S3) | 38.18 | 38.32 | 38.30 | ||
| Support 4 (S4) | 38.21 |
